💡 JAMA Insights: #SleepHealth and #obesity are linked, with insufficient sleep quantity and poor sleep quality associated with weight gain, less healthy diet, and incident obesity. https://t.co/SEj9dwNHiW https://t.co/JbPah4BwDr

In a claims analysis, 28.1% of patients with PsA had ≥1 predictor of IBD development at PsA diagnosis. 📊Which predictors had the highest association with future IBD? Click to learn more: https://t.co/dLeCyOBgC2 Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/2WmksJK6ou

QD Clinic: Addressing Severe Gout Flares Dr. Eric Dein, Summit, NJ, discusses a difficult-to-treat case of gout. https://t.co/tochY0BUBj https://t.co/9hQ13cDY9s

Retrospective study, 41 pediatric Behcets Dz pts looked at Inflam. indices (NLR, SII, PIV, CRP/albumin) vs controls. BD systemic involvement in 68%, CNS dz in 10%, Vascular Dz in 12% & major organ dz 46%. Inflamm indices significantly higher in BD w/ systemic, CNS, & Vasc https://t.co/wHiBIaOWWU

Gout & Metabolic Syndrome Dr. John Fitzgerald, Los Angeles, hates the expression "It's only Gout." https://t.co/0JipL3kgcM https://t.co/jszxYAfZwa

Four Decades of Gout Management During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued, primary attention. https://t.co/pTcEtEfQtc https://t.co/yK79xyrEHI

Treatment goals in gout: aim for remission! Rheumatologists are used to the concept of disease remission as this is a treatment goal we use for many chronic rheumatic diseases in our clinical practice. Recently, G-CAN (the Gout and Crystal Arthritis Network), endorsed a https://t.co/PP2NBqvo7E

New Avacopan Analysis Sent to FDA After data manipulation allegations, the FDA has been calling for the vasculitis drug to be pulled from the market since January. Amgen has submitted a third-party review of avacopan's (Tavneos) pivotal trial data and other analyses to the FDA https://t.co/TdLWRMPvnR

Tips for safe use of allopurinol https://t.co/Yn1u1bEj4F https://t.co/lMWPI9OsVe

6 mos. RCT of low-dose baricitinib (Bari) plus danazol for refractory ITP (n 216); Pts Rx w/ either Bari+DNZ vs DNZ alone. At 6-mos a durable response was seen in 45% of Bari+DNZ vs 20% in DNZ monotherapy (P < 0.001). AEs were equal (48% vs 45%), More studies needed on this https://t.co/YbF49ZNA0E

Machine learning study of 657 multiethnic Lupus pts - 14% had organic & 30% had neuropsychiatric damage. High Glucocorticoid dose was the strongest predictor or organic Dz. NP damage predicted by MD global, fatigue, pain, & steroids https://t.co/LVK57LxKk6 https://t.co/VLisZT7ReY

Cerebral atrophy is common in SLE - assoc w/ age (OR 1.1), higher education (0.22), NPSLE (OR 4.6), cognitive impairment & lower dsDNA titers. 70 pts (mean age 40, Dz dur 12yrs). Cerebral atrophy 53% (mostly 76% mild). https://t.co/ewRmNj8zNA https://t.co/yT8TCXZREA